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ABSTRACT 
Purpose: Selegiline HCl (SGN) is indicated for treatment of Parkinson’s disease (PD). Its mode of action involves inhibition of MAO-B enzyme. It 
shows extensive hepatic first pass metabolism and low biological half life of 1.2 -2 hours. It results in 10 % bioavailability on oral administration. 
To circumvent these problems, it was envisaged to develop transdermal film of selegiline HCl for management of PD.    
Method: The transdermal film were developed using ethyl-vinyl acetate (EVA) as a film former. Dibutyl phthalate (DBT) and triethyl citrate 
(TEC) were used as plasticizers in concentrations 10 to 20 % of polymer weight. Oleic acid and linoleic acid were used as penetration enhancers 
in concentrations 0.5 to 2 %.  Effect of concentration of plasticizers and penetration enhancers were investigated on ex-vivo skin permeation of 
SGN. The films were subjected to evaluation parameters like weight variation, thickness, drug content, skin irritancy and stability studies.         
Results: The transdermal film containing 20 % w/w of TEC of polymer weight has resulted in smooth flexible film. Maximum drug diffusion in 
ex-vivo permeation was observed with 20 % w/w of TEC of polymer weight. The transdermal film containing 2 % w/w of linoleic acid has shown 
maximum dug diffusion in ex-vivo permeation studies.    
Conclusion: SGN embedded transdermal films were successfully developed using EVA as a film former. TEC and linoleic acid has shown 
enhanced skin diffusion of drug as compared to DBT and oleic acid. Hence it is a promising approach for transdermal delivery of SGN.    
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Neurodegenerative diseases effects memory induced 
cognitive damages, affects the ability to speak, move and 
breathing. It is predicted that neurodegenerative diseases 
will affect 135 million population of world by 2050. The 
neurodegenerative diseases are age dependant, and going 
progressively in recent years 1. There are various examples 
of neurodegenerative diseases viz. Alzheimer’s disease, 
Parkinson’s disease (PD), Huntington’s disease and 
spinocerebellar ataxias. PD disease affects motor dysfunction 
resulting in rigidity, bradykinesia, and tremor. These types of 
symptoms are shown due to the low level of dopamine in 
nigrostriatal pathway. Lewy body formation is one of the 
reasons for induction of PD 2,3,4,5. 
In recent years PD is the second most common 
neurodegenerative disease 6. Around 1-2 % of the population 
those over the age of 65 years go through PD and frequencies 
of PD are increases with age 7. The prevalence of PD is likely 
to double over by 2030 8. The therapy of PD involves MAO-B 
inhibitors and combinations of carbidopa and levodopa. 
Levodopa and carbidopa are the remedy for Parkinson’s 
disease 9. In spite of balanced remedy, levodopa therapy 
gives less response to treatment after couple of months and 
observed several on-off sequences 10. In the primary phase of 
disease, monotherapy of monoamine oxidase B (MAO-B) 
inhibitors are favoured for controlling the symptoms of PD 
11,12. The first line treatment for PD is carried out with 
selegiline which is selective and irreversible inhibitor of 
MAO-B enzymes 13. Oral bioavailability of selegiline is low 
due to extensive hepatic first pass metabolism. It is 
metabolised in liver by the enzyme cytochrome P450 to N-
desmethyl selegiline, levomethamphetamine, levpampheta-
mine. There is no requirement of adjusting the dose of 
selegiline in patients with liver and kidney failure because its 
metabolites are quickly appear in urine and faeces 14. The 
drug administered by transdermal route of administration, 
avoids its hepatic first pass metabolism. Moreover 
transdermal drug delivery provides steady state plasma 
concentration of drug 15,16,17. Transdermal matrix patches 
would be the better option regarding the patient compliance, 
human health benefit in sustain use of drug and favoured by 
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health care provider throughout the complete treatment of 
disease18. The purpose of the release controlling membrane 
is one of the techniques to modulate the drug release. Among 
the various numbers of polymers, ethylene-vinyl acetate 
(EVA) copolymer is heat processible, elastic and cheaper 
material. The EVA membrane has been used as rate 
controlling membrane for controlled delivery of drug19. 
For the development of film a plasticizer usually in 
concentration 10 to 20 % of polymer weight is added to 
impart flexibility to the film. It provides plasticity to the film 
resulting in its smooth appearance. Plasticizers promote 
drug release from polymeric matrix film due to creation of 
channels in film. The penetration enhancer acts by one or 
more that one mechanism at intercellular lipidic domain of 
stratum corneum membrane of skin resulting in enhanced 
permeation of drug. The disorderliness at intercellular lipids 
leads to the enhanced  permeation of hydrophilic and 
hydrophobic drugs. The penetration enhancers act on bound 
water between the charged hydrophilic groups of the lipids 
of stratum corneum resulting in its expansion and the 
penetration of hydrophilic drug is increased. The 
denaturation of alpha keratin present in corneocyte of 
stratum corneum also results in enhanced permeation of 
drug.                             
It was envisaged to develop the SGN embedded transdermal 
drug delivery system and study the effect of plasticizers and 
penetration enhancers on the transdermal penetration of 
drug from film. In present investigation we envisaged to 
study the effect of dibutyl phthalate and triethyl citrate as 
well penetration enhancers oleic acid and lenoleic acid on 
transdermal penetration of SGN.  
MATERIALS AND METHOD 
Selegiline Hydrochloride (SGN) was obtained as a gift sample 
from Intas Pharmaceuticals Ltd., Ahmedabad, India. 
Ethylene-vinyl acetate was purchased from Sigma-Aldrich 
Chemicals, Banglore, India. Di-butyl phthalate, and tri-ethyl 
citrate were purchased from HiMedia, Mumbai, India. All 
other solvents and reagents were used of analytical grade. 
Formulation of transdermal film 
The transdermal film comprising ethylene vinyl acetate and 
SGN was developed by solvent casting method using film 
former machine (V.J. Instruments Pvt. Ltd. India.). Accurately 
2 g EVA polymer was dissolved in 10 ml dichloromethane 
(DCM) in volumetric flask. To it SGN (18 mg) was added and 
kept on rotary shaker for 3 h. To the resulting solution either 
the plasticizer or penetration enhancers was added (Table 
1). The solution was dragged on film former platform of 
machine with help of dragger to cast a thin film. Solvent was 
allowed to evaporate for 8 hours at room temperature. The 
thin film formed was removed with the help of sharp cutter 
knife.
   
Table 1 Formulation table for SGN embedded matrix transdermal film 
Sr. No. Formulation SGN (mg) EVA 
(g) 
DCM (ml) DBT (%) TEC (%) Oleic acid 
(%) 
Linoleic acid  
(%) 
1. S1 18 2 10 10 - - - 
2. S2 18 2 10 15 - - - 
3. S3 18 2 10 20 - - - 
4. S4 18 2 10 - 10 - - 
5. S5 18 2 10 - 15 - - 
6. S6 18 2 10 - 20 - - 
7. S7 18 2 10 - - 0.5 - 
8. S8 18 2 10 - - 1 - 
9. S9 18 2 10 - - 2 - 
10. S10 18 2 10 - - - 0.5 
11. S11 18 2 10 - - - 1 
12. S12 18 2 10 - - - 2 
 
Evaluation of Transdermal Films                
Differential scanning calorimetry (DSC) 
Drug, polymer and formulation were analysed by differential 
scanning calorimetry (DSC) studies by using Mettler-Toledo 
DSC apparatus, Zurich, Switzerland. All samples were 
weighed into aluminium pans and subjected to heating at a 
rate of 10 ℃/ min from 0 ℃ to 400 ℃. Nitrogen gas at a flow 
rate of 40 ml/min was used as a purge gas in DSC analysis. 
The results were analysed using STARe SW 10.00 software. 
(Mettler-Toledo DSC apparatus, Zurich, Switzerland). 
Fourier transform infrared spectrometry (FT-IR) 
In FT-IR studies, SGN and EVA polymer were individually 
triturated and mixed well with potassium bromide in 1:1 
ratio. The samples were compressed under 
10 t/nm2 pressure and scanned in 400 to 4000 cm−1 
stretching frequency range. The FT-IR spectrum of 
formulation was compared with spectrum of drug and 
polymer. The shift in the stretching frequency of drug in 
presence of polymer was investigated to determine physical 
interactions between SGN and EVA. 
Physical appearance 
The matrix transdermal films were visually inspected for 
colour, clarity, flexibility and smoothness. 
Thickness of transdermal films 
The thicknesses of the SGN embedded polymeric matrix 
transdermal films were measured at five different points 
using a digital micrometer20,21. 
Weight uniformity 
The transdermal films were dried at 40 ℃. Three films from 
each formulation batch were accurately weighed on digital 
balance22. 
Content uniformity of drug in transdermal films 
To assure uniform distribution of SGN in the transdermal 
films, a content uniformity test was carried out. Five samples 
of each 2 × 2 cm representing the different segments of the 
films were cut and weighed. The SGN was extracted from the 
film using 10 ml DCM in rotary shaker at 250 rpm for 3 h. It 
was diluted with distilled water and estimated 
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spectrophotometrically on UV- spectrophotometer at 204 
nm23. 
Tensile strength and percentage elongation 
The maximum force required to break the film was recorded 
as a tensile strength. The weight was gradually increased so 
as to increase stretching force to break the matrix 
transdermal film. The tensile strength and percent 
elongation were measured using JJ Lloyd instruments limited 
(Southampton, England) 24. 
Folding endurance 
The specific area of matrix transdermal film was cut 
accurately and repeatedly folded at a same place till the film 
was broke. The numbers of counts up to breakage of film 
were recorded as folding endurance 25. 
Percent moisture uptake  
The accurately weight matrix transdermal film was kept in 
desiccators at room temperature for 24 h. To maintain the 
65 % relative humidity in desiccators, it was filled with 
saturated potassium chloride solution. After 24 h, matrix 
transdermal film was accurately reweighed and calculated 
the percent moisture using equation (1) 26. 
                       
                   –                      
                    
× 100    
eq.(1) 
Ex-vivo permeation study 
The ex-vivo permeation study was carried out using diffusion 
cell apparatus (Orchid Scientific Pvt. Ltd, Nasik, India). The 
male rat abdomen was trimmed and skin samples were 
obtained. The removed skin was washed with ethyl alcohol 
to remove excess fat from the skin and soaked in phosphate 
buffer pH 7.4 before permeation study. The developed 
transdermal film piece of size 3.14 cm2 was placed on 
epidermal side of skin in the donor compartment of diffusion 
cell apparatus. Phosphate buffer pH 7.4 was filled in the 
receptor compartment of the diffusion cell apparatus and 
after predetermined time interval 2 ml of sample was 
withdrawn at 0,,2,4,6,8,10,12,16,20,24,36,48,60 and 72 h and 
replaced it with fresh receptor fluid. The samples were 
analysed for drug content at 210 nm using UV-visible 
spectrophotometer (UV-1800, Shimadzu, Mumbai, India). 
Skin irritation study 
The skin irritation tests were performed on healthy albino 
wistar rats weighing between 200 g to 300 g. The wistar rats 
were kept in cages with free allowance of food and water 
according to standard protocol of laboratory. The dorsal 
abdominal skin was carefully trimmed to avoid any damage 
to skin. A 0.8 % aqueous solution of formalin was used as a 
standard skin irritant. SGN embedded matrix transdermal 
film was applied to the rats and compares the score of 
erythema with a standard irritant solution. The score of 
erythema was recorded by draize scoring method27. 
Stability study 
Stability study was carried out according to the ICH 
guidelines. Optimized formulation was kept in stability 
chamber (REMI, Mumbai, India) at a condition 40 ℃ and 75 
% RH (Relative humidity). The formulations were observed 
for physical changes, weight uniformity, moisture uptake and 
strength of the transdermal matrix films. 
RESULTS AND DISCUSSION 
DSC studies 
The DSC endotherm of selegiline HCl, EVA polymer and their 
physical mixture was recorded from ambient to 400 ℃ at a 
heating rate of 10 ℃/min. The comparison of thermal 
transitions has revealed that selegiline HCl has shown the 
melting transition from 142.77 ℃ to 148.47 ℃ as a melting 
temperature range with a peak at 144.74 ℃. The enthalpy of 
endothermic transition was found to be -149.68 J/g. The 
polymer EVA has shown the onset at 64.48 ℃ and end set at 
93.75 ℃ indicating as temperature range with melting peak 
at 82.83 ℃ and enthalpy value -81.23 J/g. The physical 
mixture has not shown any significance change in the 
melting temperature of drug and polymer as indicated by the 
melting peak at 148.07 ℃ for selegiline HCl and 77.94 ℃ for 
EVA. It can be concluded that the physical mixture of drug 
and polymer does not have any potential to form either 
adduct or new chemical entity. No interaction was observed 
in physical mixture of drug and polymer. 
 
 
Figure 1: DSC thermogram of selegiline HCl 
 Bali et al                                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(2):344-351 
ISSN: 2250-1177                                                                                     [347]                                                                                     CODEN (USA): JDDTAO 
 
Figure 2: DSC thermogram of ethylene-vinyl acetate 
 
Figure 3: DSC thermogram of selegiline hydrochloride and ethylene-vinyl acetate polymer physical mixture 
 
Fourier transform infrared spectrometry (FT-IR) 
The FTIR spectra of drug, polymer and their physical mixture 
were recorded from 400 to 4000 cm-1 using KBr press pellets 
technique. The FTIR stretching frequencies of selegiline HCl 
was observed at 1093 and 1153 cm-1 representing C-O 
stretching 1292 cm-1 (C-N stretch), 1434 cm-1 (C=C), 1602 
cm-1 (N-H), 1776 cm-1 and 1826 cm-1  (C=O), 2123 cm-1 
(C≡C), 2943 cm-1 and 3228 cm-1 (OH stretching) these 
stretching peaks were not altered significantly in the 
physical mixture of drug and polymer. It was concluded that 
no physical interaction was occurred in drug and polymer. 
   
 
Figure 4: FT-IR spectra of selegiline HCl 
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Figure 5: FT-IR spectra of ethylene-vinyl acetate 
 
Figure 6: FT-IR spectra of selegiline HCl and ethylene-vinyl acetate polymer physical mixture 
Physical appearances 
The transdermal films with increasing concentrations of DBT 
as a plasticizer from 10, 15 and 20 percent as shown 
decreasing brittleness of films. Also the films was found to be 
transparent with 20 % dibutyl phthalate and triethyl citrate. 
The films were found to be transparent, clear, smooth and 
flexible in appearance.  
Thickness 
 The thickness of transdermal films was found to be 0.78 ± 
0.13mm. The weights of 2 × 2 cm unit dimension of 
transdermal films was found to be uniform. 
Weight uniformity 
The weight uniformity of randomly selected matrix 
transdermal films were found to be in the range of 1.9 g to 
2.1 g.     
Content uniformity 
The content uniformity of 2 × 2 cm transdermal films was 
found to be comply within the acceptable limit of 90 to 110 
% selegiline HCl.  
Tensile strength  
The tensile strength of transdermal film was found to be 0.25 
to 0.39 kg/cm2. The percent elongation of transdermal films 
found in the range 17 to 19 %.  
Folding endurance  
The folding endurance of films were found in the range of 
290 to 345 
Percent moisture uptake 
The percent moisture uptakes of films were found to be 2 to 
3 %. 
Ex-vivo permeation study 
Effect of plasticizers on ex-vivo permeation  
Plasticizers creates pores in the polymer matrix their by 
increases drug release which in turns increases amount of 
drug diffusion across skin. The film rigidity gets reduced due 
to the action of plasticizers on polymeric chains resulting in 
enhanced flexibility of film. The effect of plasticizers study 
viz. DBT and TEC has shown enhanced ex vivo drug diffusion 
across the rat skin28.  
The diffusion of SGN was found to be enhanced with 
increasing concentration of TEC from 10 to 20 %. In the ex-
vivo skin permeation studies transdermal film containing 
SGN, a lag time of 4 h was observed for the drug to appear in 
the receptor compartment. TEC in concentrations 10, 15, and 
20 %of polymer weight has shown flux values of 37.63, 45.36 
and 53.87 (µg/cm2/h) respectively. The hydrophobic 
plasticizer DBT has shown comparatively lesser drug 
diffusion than TEC (Figure 7 and 8). DBT in concentrations 
10, 15, and 20 % of polymer weight has shown flux values of 
30.16, 33.41, and 36.14 (µg/cm2/h). The wicking and 
channelling action of plasticizer on polymeric chains 
increases mobility of drug polymer matrix.TEC as plasticizer 
has shown enhanced permeation of SGN as compared to 
DBT.
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Figure 7: Effect of DBT on ex-vivo permeation of SGN 



































Figure 8: Effect of TEC on ex-vivo permeation of SGN 
 
Effect of penetration enhancers on ex-vivo permeation  
Penetration enhancers acts on the intercellular lipid of the 
stratum corneum of the skin resulting in disorderliness in 
the sphingo lipids, ceramides and other lipidic components 
their by an increasing fluidity of intercellular lipids. The 
orderly array of lipid head group and non-polar tails gets 
disorganise due the action of penetration enhancer leading 
to enhanced permeation through free space of intercellular 
lipid domain. The enhanced fluidity permits more drug 
diffusion across intercellular lipids. Number of carbon atoms 
in fatty acids and position of double bonds affects the 
penetration characteristics of fatty acid as penetration 
enhancers29. 
Oleic acid is monounsaturated omega-9 fatty acid where as 
linoleic acid is polyunsaturated omega-6 essential fatty acid 
with two double bonds in cis configuration. In the  ex-vivo 
skin permeation studies of transdermal film containing SGN, 
lag time of 4 h was observed for the drug to appear in the 
receptor compartment. Oleic acid in concentrations 0.5, 1, 
and 2 %  concentrations has shown flux values of 42.04, 
47.83, and 59.12 (µg/cm2/h) respectively. Linoleic acid in 
concentrations 0.5, 1, and 2 % has shown flux values of 
49.87, 58.79, and 69.11 (µg/cm2/h) respectively in ex-vivo 
skin permeation studies. Linoleic acid was found to show 
enhanced diffusion of SGN as compared to oleic acid. 
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Figure 9: Effect of oleic acid on ex-vivo permeation of SGN across skin 
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Figure 10: Effect of linoleic acid on ex-vivo permeation of SGN  
Skin irritation study 
The SGN embedded matrix transdermal films which showed 
the maximum drug diffusion in ex-vivo studies were applied 
to healthy albino wistar rats. Score of draize test were 0 in 
every determination of erythema and edema, this indicates 
that the primary irritation were absent in rats. 
Stability study 
Effect of temperature 
All the optimized SGN matrix transdermal films showed the 
high stability upon storage at 40 ℃ and there were observed 
no physical change, weight uniformity and strength of the 
matrix films as compared to freshly formulated matrix 
transdermal films.   
Effect of humidity 
All the optimized formulations were showed the slight 
increase in their weight at 75 % Relative humidity. There 
were no physical changes observed in matrix transdermal 
films.   
CONCLUSION 
Transdermal film formulation containing selegiline HCl were 
developed by film casting method using ethylene-vinyl 
acetate as film former. The effect of plasticizer dibutyl 
phthalate and triethyl citrate and penetration enhancers 
oleic acid and linoleic acid were studied in increasing 
concentration on ex-vivo permeation across skin using 
phosphate buffer 7.4 pH as receptor medium 
Triethyl citrate has shown enhance drug diffusion across 
skin from transdermal film as compared to dibutyl phthalate.  
Linoleic acid as penetration enhancer showed better 
penetration across the skin than oleic acid. Transdermal 
drug delivery systems provide the better control on drug 
release resulting in predictable steady state blood plasma 
concentration of SGN for the management of parkinson’s 
disease. 
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